Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Medigene AG. (1/19/18). "Press Release: Medigene Announces Participation at Six Upcoming Investor and Scientific Conferences". Planegg.

Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Oddo (Group)
Products Product BioCapital Europe 2018 Amsterdam
  Product 2 ASCO-SITC Clinical Immuno-Oncology Symposium 2018 San Francisco
Persons Person Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
  Person 2 Taapken, Thomas (Medigene 201701–201808 CFO before Epigenomics + Biotie/elbion + DVC + Burrill + Hoechst LEFT 8/18)
     


Planegg - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming investor and scientific conferences:

Precision Medicine World Conference (PMWC) 2018
Date: 22 - 24 January 2018
Location: Mountain View, CA, USA
Dr. Kai Pinkernell, Chief Medical Officer of Medigene, will give a presentation during the PMWC 2018 Immunotherapy Showcase on 23 January at 2 pm on the topic "Using cutting-edge technologies to develop TCR-based immunotherapies".

ASCO-SITC Clinical Immuno-Oncology Symposium
Date: 25 - 27 January 2018
Location: San Francisco, CA, USA

BioCapital Europe
Date: 6 February 2018
Location: Amsterdam, Netherlands
Julia Hofmann, Head of Public & Investor Relations at Medigene, will hold a company presentation on 6 February at 4.40 pm.

Immuno-Oncology 360°
Date: 7 - 9 February 2018
Location: New York, USA
Dr. Thomas Taapken, CFO of Medigene, takes part in the discussion panel entitled "Raising Money in the Current Climate" on 9 February at 2 pm.

CAR-TCR Summit Europe 2018
Date: 20 - 22 February 2018
Location: London, UK
Prof. Dolores Schendel, CEO and CSO of Medigene, will hold a company presentation on 22 February.

ODDO - 11th German Conference
Date: 21 - 22 February 2018
Location: Frankfurt; Germany


Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com


This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.


Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

   
Record changed: 2018-01-24

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top